



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/540,601	06/23/2005	Benito Munoz	MS0018YP	4252

210 7590 03/19/2007  
MERCK AND CO., INC  
P O BOX 2000  
RAHWAY, NJ 07065-0907

EXAMINER
----------

NOLAN, JASON MICHAEL

ART UNIT	PAPER NUMBER
----------	--------------

1626

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	03/19/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/540,601	<b>Applicant(s)</b> MUNOZ ET AL.	
	<b>Examiner</b> Jason M. Nolan, Ph.D.	<b>Art Unit</b> 1626	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 16 January 2007.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 20,21 and 31-42 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 21,32,37-40 and 42 is/are allowed.
- 6) ☒ Claim(s) 20,31,33-36 and 41 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date <u>06/23/2005</u> . | 6) <input type="checkbox"/> Other: _____  |

### **DETAILED ACTION**

**Claims 20, 21 & 31-42** are currently pending in the instant application; of which: **Claims 20, 21, 31 & 32** are currently amended and **Claims 33-42** are new. **Claims 1-19 & 22-30** are canceled.

### ***Information Disclosure Statement***

Applicants' information disclosure statement (IDS), filed on 06/23/2005 has been considered. Please refer to Applicants' copy of the 1449 submitted herein.

### ***Priority***

This application is a 371 of PCT/US04/00424, filed on 01/09/2004.

Acknowledgement is made of Applicants' claim for benefit of US Provisional Patent

Applications 60/439,965, filed on 01/14/2003 and 60/439,847, filed on 01/14/2003. Said claim has been made in the ADS and/or in the first paragraph of the Specification.

### ***Claim Rejections - 35 USC § 112, 1<sup>st</sup> Paragraph***

The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

**Claims 20, 31, 33-36 & 41** are rejected under 35 U.S.C. § 112, first paragraph, because the specification, while enabling for a method for the treatment of Alzheimer's disease, does not reasonably provide enablement for a method for preventing, delaying

Art Unit: 1626

or reversing the progression of Alzheimer's disease. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

As stated in the MPEP 2164.01(a), "There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is 'undue'."

*In re Wands*, 8 USPQ2d 1400 (1988), discusses the following factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. § 112, first paragraph:

1. *The nature of the invention;*
2. *The state of the prior art;*
3. *The predictability or lack thereof in the art;*
4. *The amount of direction or guidance present;*
5. *The presence or absence of working examples;*
6. *The breadth of the claims;*
7. *The quantity of experimentation needed; and*
8. *The level of skill in the art*

each of which is discussed in turn below.

#### ***The nature of the invention***

The nature of the invention is a method for the treatment of Alzheimer's disease comprising administering to a patient a compound of the Formulae I or I'.

#### ***The state of the prior art and the predictability or lack thereof in the art***

The state of the prior art, namely pharmacological art, involves screening *in vitro* and *in vivo* to determine if the compounds exhibit desired pharmacological activities,

Art Unit: 1626

which are then tested for their efficacy on human beings. There is no absolute predictability even in view of the seemingly high level of skill in the art. The existence of these obstacles establishes that the contemporary knowledge in the art would prevent one of ordinary skill in the art from accepting any therapeutic regimen on its face. The instant claimed invention is highly unpredictable as discussed below.

It is noted that the pharmaceutical art is unpredictable, requiring each embodiment to be individually assessed for physiological activity. *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18 (CCPA 1970) indicates that the more unpredictable an area is, the more specific enablement is necessary in order to satisfy the statute. *In the instant case*, the claimed invention is highly unpredictable since one skilled in the art would recognize that a group of compounds and compositions may provide a treatment for Alzheimer's disease, but it does not mean that the same group of compounds and compositions may prevent, delay or reverse the progression of Alzheimer's disease.

From a recent review by Citron (*Nature Reviews Neuroscience* **2004**, 5, 677-685): Alzheimer's disease (AD) affects more than 12 million individuals worldwide, and death occurs, on average, within nine years of diagnosis. The current standard of care for mild to moderate AD includes treatment with acetylcholinesterase inhibitors, and an NMDA antagonist has recently been approved for the treatment of advanced AD in the US. Two main disease mechanism-based approaches, which have been studied for more than 10 years, are based on the involvement of two proteins, amyloid- $\beta$  ( $A\beta$ ) and tau, in AD pathology.  $A\beta$  is the main constituent of senile plaques, one of the key pathological characteristics of AD. Genetic and pathological evidence strongly supports

the amyloid cascade hypothesis of AD, which states that amyloid- $\beta$  42 ( $A\beta$  42), a proteolytic derivative of the large transmembrane protein amyloid precursor protein, has an early and vital role in all cases of AD. The most direct approach in anti-amyloid therapy is the reduction of  $A\beta$  42 production.

***The amount of direction or guidance present and the presence or absence of working examples***

There is no direction or guidance provided which supports Applicant's claimed method for preventing, delaying or reversing the progression of Alzheimer's disease as indicated. The direction or guidance present in Applicants' Specification for a method of using the compounds of Formulae I and I' to treat Alzheimer's disease include the *Assays for Determining Biological Activity* (Protocol for measuring  $A\beta$  1-40 and  $A\beta$  1-42 levels) is found on pages 25-26.

***The breadth of the claims, quantity of experimentation, and level of skill in the art***

Claims 20, 31, 33-36 & 41 are drawn to a method for preventing, delaying or reversing the progression of Alzheimer's disease. In order to prevent a disease, one would need to precisely identify those subjects likely to acquire such a disease, administer Applicant's claimed invention, and then demonstrate that if the identified subject did not develop the disease, such an effect was the direct result of administration of the claimed invention. Furthermore, in the case of Alzheimer's disease, the ultimate cause of the disease is unknown. Current drugs improve

Art Unit: 1626

symptoms, but do not have profound disease-modifying effects. No medical tests are available to diagnose Alzheimer's disease conclusively pre-mortem. Expert clinicians who specialize in memory disorders can now diagnose AD with an accuracy of 85–90%, but a definitive diagnosis of Alzheimer's disease must await microscopic examination of brain tissue, generally at autopsy.

Because of the aforementioned reasons, a person of skill in the art could not practice the claimed invention herein, or a person of skill in the art could practice the claimed invention herein only with undue experimentation and with no assurance of success. Canceling **Claims 20, 31, 33-36 & 41** would overcome this rejection.

***Allowable Subject Matter***

**Claims 21, 32, 37-40 & 42** are free of the prior art; nothing known anticipates or renders said claims obvious. As discussed above, the most direct approach in anti-amyloid therapy is the reduction of A $\beta$ 42 production, an approach that has been studied for over ten years. A structure and keyword search revealed that no compounds have been published which are implicated as anti-amyloid compounds.


Art Unit: 1626

***Telephone Inquiry***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jason M. Nolan, Ph.D.** whose telephone number is **(571) 272-4356** and electronic mail is **Jason.Nolan@uspto.gov**. The examiner can normally be reached on Mon - Fri (9:00 - 5:30PM). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Joseph M<sup>c</sup>Kane** can be reached on **(571) 272-0699**. The fax phone number for the organization where this application or proceeding is assigned is **571-273-8300**. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Jason M. Nolan, Ph.D.  
Examiner  
Art Unit 1626



Joseph K. M<sup>c</sup>Kane  
Supervisory Patent Examiner  
Art Unit 1626  
Date: March 14, 2007